Tuebingen, Germany and Houston, Texas, May 26, 2021 -- Immatics N.V.
(NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company
active in the discovery and development of T cell-redirecting cancer
immunotherapies, today announced changes to its Board of Directors.
Christof Hettich, L.L.D., Managing Partner and founding member of the
dievini Hopp BioTech holding GmbH & Co. KG, has decided to step down
from Immatics' Board of Directors. He has been a member of Immatics'
Board of Directors since 2006. Former Immatics Board member Friedrich
von Bohlen und Halbach, PhD, Managing Partner and co-founder of dievini
Hopp BioTech Holding GmbH & Co. KG has been nominated to be his
successor. The election will take place at Immatics' Annual General
Meeting on June 17, 2021.
Peter Chambré, Chairman of Immatics' Board of Directors commented:
"I would like to thank Christof Hettich on behalf of my fellow Board
members and the Immatics' management team for his tremendous
contributions to the company for more than 15 years. He has been
instrumental in the development of Immatics over this period. We would
be delighted to welcome Friedrich von Bohlen und Halbach back to our
Board of Directors."
Dr. Friedrich von Bohlen und Halbach is Managing Partner and co-founder
of dievini Hopp BioTech Holding GmbH & Co. KG, the company managing the
life science activities and investments of Dietmar Hopp, co-founder of
SAP, and his family. Friedrich von Bohlen und Halbach holds a diploma in
biochemistry from the University of Zurich and a PhD in neurobiology
from the Swiss Federal Institute of Technology (ETH) in Zurich. He held
various positions at Fresenius AG, FAG Kugelfischer KGaA and WASAG
Chemie AG. In 1997 he founded LION bioscience AG whose CEO he was for
seven years. He is chairman of the Board of Apogenix AG and Novaliq GmbH,
and board member of CureVac AG, Heidelberg Pharma AG and Co-Chair of the
Evaluation Board of the Wyss Translational Center Zurich. Friedrich von
Bohlen und Halbach is also co-founder and Managing Director of Molecular
Health GmbH. Friedrich von Bohlen und Halbach has been a member of
Immatics' Board of Directors from 2006 to 2020.
- END -
Immatics combines the discovery of true targets for cancer
immunotherapies with the development of the right T cell receptors with
the goal of enabling a robust and specific T cell response against these
targets. This deep know-how is the foundation for our pipeline of
Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships
with global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
For regular updates about Immatics, visit www.immatics.com. You can also
follow us on Twitter
For more information, please contact:
For media enquiries Investor Relations Contact
Jacob Verghese or Stephanie May John Graziano
Trophic Communications Solebury Trout
Phone: +49 89 2388 7731 Phone: +1 646-378-2942
Immatics N.V. Investor Relations Contact
Anja Heuer Jordan Silverstein
Corporate Communications Head of Strategy
Phone: +49 89 540415-606 Phone: +1 281-810-7545
-- PDF Version
(END) Dow Jones Newswires
May 26, 2021 07:00 ET (11:00 GMT)